AR091237A1 - Composiciones que comprenden un aptamero anti factor de crecimiento derivado de plaquetas (anti-pdgf) y un antagonista de factor de crecimiento de endotelio vascular (vegf) - Google Patents

Composiciones que comprenden un aptamero anti factor de crecimiento derivado de plaquetas (anti-pdgf) y un antagonista de factor de crecimiento de endotelio vascular (vegf)

Info

Publication number
AR091237A1
AR091237A1 ARP130101931A AR091237A1 AR 091237 A1 AR091237 A1 AR 091237A1 AR P130101931 A ARP130101931 A AR P130101931A AR 091237 A1 AR091237 A1 AR 091237A1
Authority
AR
Argentina
Prior art keywords
growth
compositions
factor
pdgf
vegf
Prior art date
Application number
Other languages
English (en)
Inventor
Everett Richard
Seon Chang Byeong
Original Assignee
Ophthotech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ophthotech Corp filed Critical Ophthotech Corp
Publication of AR091237A1 publication Critical patent/AR091237A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Composiciones que comprenden un aptámero anti factor de crecimiento derivado de plaqueta (anti-PDGF) y un antagonista de factor de crecimiento del endotelio vascular (VEGF). En algunas formas de realización, las composiciones de la presente son útiles para el tratamiento y prevención de enfermedades oftalmológicas.
ARP130101931 2012-06-01 2013-05-31 Composiciones que comprenden un aptamero anti factor de crecimiento derivado de plaquetas (anti-pdgf) y un antagonista de factor de crecimiento de endotelio vascular (vegf) AR091237A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261654672P 2012-06-01 2012-06-01
US201361778208P 2013-03-12 2013-03-12

Publications (1)

Publication Number Publication Date
AR091237A1 true AR091237A1 (es) 2015-01-21

Family

ID=49674074

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130101931 AR091237A1 (es) 2012-06-01 2013-05-31 Composiciones que comprenden un aptamero anti factor de crecimiento derivado de plaquetas (anti-pdgf) y un antagonista de factor de crecimiento de endotelio vascular (vegf)

Country Status (18)

Country Link
US (1) US20150182623A1 (es)
EP (1) EP2854844A4 (es)
JP (1) JP2015519373A (es)
KR (1) KR20150033620A (es)
CN (1) CN104619335A (es)
AR (1) AR091237A1 (es)
AU (1) AU2013267310A1 (es)
CA (1) CA2874412A1 (es)
CL (1) CL2014003233A1 (es)
CO (1) CO7240393A2 (es)
EA (1) EA201492289A1 (es)
HK (1) HK1207983A1 (es)
IL (1) IL235797A0 (es)
MX (1) MX2014014445A (es)
PH (1) PH12014502577A1 (es)
SG (1) SG11201407981RA (es)
TW (1) TW201400122A (es)
WO (1) WO2013181495A2 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK4374873T3 (da) 2013-07-12 2025-11-03 Astellas Us Llc Middel til brug ved behandling eller forebyggelse af oftalmologiske tilstande
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
CA2958017A1 (en) * 2014-08-11 2016-02-18 Ophthotech Corporation Methods for treating or preventing ophthalmological conditions
CN112656939B (zh) * 2014-09-22 2023-12-08 正大天晴药业集团股份有限公司 一种针对血管内皮生长因子的人源化抗体的药物组合物
BR112017014376A2 (en) 2015-01-28 2018-05-02 Pfizer Inc. stable aqueous formulation of vascular endothelial growth antifactor (vegf) antibodies and use
CN105806830B (zh) * 2015-12-10 2019-01-29 北京联众泰克科技有限公司 一种稳定的hrp酶促化学发光底物液、其制备方法及应用
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
EP3407868A1 (en) * 2016-01-26 2018-12-05 Formycon AG Liquid formulation of a vegf antagonist
CA3010623A1 (en) 2016-02-04 2017-08-10 Jinsong Ni Antibody-drug synergism technology for treating diseases
BR112018017031A2 (pt) * 2016-02-23 2019-01-22 Sesen Bio Inc formulações de antagonista de il-6 e usos das mesmas
EP3541365A1 (en) * 2016-11-21 2019-09-25 Just Biotherapeutics, Inc. Aflibercept formulations and uses thereof
KR101861163B1 (ko) * 2017-04-26 2018-05-25 삼천당제약주식회사 안과용 약학 조성물
MA50908A (fr) 2017-11-17 2020-09-23 Amgen Inc Formulations de protéines de fusion vegfr-fc
WO2019099965A1 (en) * 2017-11-20 2019-05-23 Just Biotherapeutics, Inc. Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof
JP2021514656A (ja) 2018-03-02 2021-06-17 コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． Ｉｌ−６抗体ならびにその融合構築物およびコンジュゲート
WO2019210097A1 (en) * 2018-04-25 2019-10-31 Vitrisa Therapeutics, Inc. Aptamers with stability, potency or half-life for enhanced safety and efficacy
MY204232A (en) 2018-05-10 2024-08-16 Regeneron Pharma High concentration vegf receptor fusion protein containing formulations
EP3870145A1 (en) * 2018-10-26 2021-09-01 Amgen Inc. Formulations comprising a tris buffer and a protein
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
KR20210077645A (ko) * 2019-12-17 2021-06-25 주식회사 프로젠 신규 주사제 제형
CN115066262B (zh) * 2020-03-04 2025-07-15 上海复宏汉霖生物技术股份有限公司 一种包含贝伐珠单抗的药物配制剂
EP4186492A4 (en) * 2020-07-24 2024-08-14 Pangen Biotech Inc. Ophthalmic liquid composition

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2536912C (en) * 2003-08-27 2015-03-31 Eyetech Pharmaceuticals, Inc. Combination therapy for the treatment of ocular neovascular disorders
US20060182783A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
WO2005110374A1 (en) * 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
LT2944306T (lt) * 2006-06-16 2021-02-25 Regeneron Pharmaceuticals, Inc. Vfgf antagonisto kompozicijos, tinkamos įvedimui intravitrealiniu būdu
CA2760687A1 (en) * 2009-05-01 2010-11-04 Ophthotech Corporation Methods for treating or preventing ophthalmological diseases
MX2013002270A (es) * 2010-08-26 2013-05-14 Abbvie Inc Inmonoglubinas de dominio variable doble y usos de las mismas.

Also Published As

Publication number Publication date
EP2854844A4 (en) 2016-11-23
CN104619335A (zh) 2015-05-13
CL2014003233A1 (es) 2015-06-19
PH12014502577A1 (en) 2015-01-21
EA201492289A1 (ru) 2015-05-29
WO2013181495A2 (en) 2013-12-05
WO2013181495A3 (en) 2014-02-13
JP2015519373A (ja) 2015-07-09
AU2013267310A1 (en) 2014-12-11
CO7240393A2 (es) 2015-04-17
HK1207983A1 (en) 2016-02-19
KR20150033620A (ko) 2015-04-01
EP2854844A2 (en) 2015-04-08
IL235797A0 (en) 2015-01-29
CA2874412A1 (en) 2013-12-05
TW201400122A (zh) 2014-01-01
US20150182623A1 (en) 2015-07-02
MX2014014445A (es) 2015-08-14
SG11201407981RA (en) 2015-01-29

Similar Documents

Publication Publication Date Title
AR091237A1 (es) Composiciones que comprenden un aptamero anti factor de crecimiento derivado de plaquetas (anti-pdgf) y un antagonista de factor de crecimiento de endotelio vascular (vegf)
CO2017004715A2 (es) Métodos y formulaciones para tratar enfermedades vasculares de los ojos
NI201600071A (es) Compuestos de inhibidor de autotaxina
CL2015000061A1 (es) Anticuerpos biespecíficos anti-vegf/anti-ang-2 y su utilización en el tratamiento de enfermedades vasculares oculares
CL2016000055A1 (es) Métodos para tratar o prevenir afecciones oftalmológicas
ECSP17018120A (es) Triazolopirazinonas como inhibidores de pde1
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
GT201600007A (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
CR20150386A (es) Composiciones de nanoparticulas de albumina y paclitaxel
MX377340B (es) Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares.
MX366317B (es) Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
CO7020876A2 (es) Composicion y metodo para el diagnostico y el tratamiento de las enfermedades asociadas a la degeneracion de las neuritas
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
DOP2017000254A (es) Imidazopirazinonas como inhibidores de pde1
UY36171A (es) Derivados heteroaromáticos bicíclicos fusionados como inhibidores de quinasa
MX389847B (es) Composiciones de ésteres de ácido cannabidiólico y usos de las mismas.
CY1121787T1 (el) Sirna και χρηση αυτων σε μεθοδους και συνθεσεις για τη θεραπεια ή/και προληψη οφθαλμικων καταστασεων
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
CY1121000T1 (el) Sirna και χρηση αυτου σε μεθοδους και συνθεσεις για την θεραπεια ή/και προληψη οφθαλμικων καταστασεων
CO2017011778A2 (es) Un inhibidor de la actividad del csf-1r y composiciones farmaceuticas que lo comprenden
MX392383B (es) Metodos para tratar afecciones oculares.
HUE051295T2 (hu) Módosított fibroblaszt növekedési faktorok-1 szembetegségek kezelésére
ECSP16061208A (es) Quinazolin-thf-aminas como inhibidores de pde1
DOP2016000263A (es) Quinazolin-thf-aminas halogenadas como inhibidores de pde1
UY34843A (es) Tratamiento de enfermedades inflamatorias oculares usando laquinimod

Legal Events

Date Code Title Description
FB Suspension of granting procedure